NV03 |
| カタログ番号GC64772 |
NV03 は、2.4 μM の Kd で、UHRF1 タンデム チューダー ドメインに結合することによる UHRF1 (PHD および RING フィンガー ドメイン 1 を持つユビキチン様)-H3K9me3 相互作用の強力かつ選択的なアンタゴニストです。 NV03には抗がん作用があります。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2448341-58-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NV03 is a potent and selective antagonist of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)- H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a Kd of 2.4 μM. NV03 has anticancer activity[1].
[1]. Senisterra G, et al. Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain. SLAS Discov. 2018 Oct;23(9):930-940.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *